For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of progression or death from any cause is lower with trastuzumab ...
Mar 24, 2022
0
6
Treating women diagnosed with one type of early-stage breast cancer with the monoclonal antibody trastuzumab after surgery reduces the risk of the cancer returning, reports a research team led by University of Saskatchewan ...
Jan 31, 2022
0
54
A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.
Jan 24, 2022
0
76
The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 ...
Jan 21, 2022
0
15
During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...
Sep 20, 2021
0
3
Thomas Hatschek, associate professor at the department of Oncology-Pathology, together with colleagues, has recently published an article in JAMA Oncology showing that a new treatment for breast cancer with an antibody linked ...
Aug 18, 2021
0
337
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results ...
Jun 29, 2020
0
2
A new study published in Oncotarget reports that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.
Jun 4, 2020
0
1
Results of the NRG Oncology clinical trial RTOG 1010 indicate that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient ...
Jun 1, 2020
0
0
The addition of the monoclonal antibody therapy trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma ...
May 29, 2020
0
0
